raloxifene

(redirected from Raloxifene hydrochloride)
Also found in: Medical.

ra·lox·i·fene

 (rə-lŏk′sĭ-fēn′)
n.
A selective estrogen receptor modulator, C28H27NO4S, used in the form of its hydrochloride primarily to treat and prevent osteoporosis in postmenopausal women.

[ral-, of unknown origin + (eth)oxy + alteration and blend of phen(yl) and -ene.]

ra•lox•i•fene

(rəˈlɒk səˌfin)
n.
a drug, C28H27NO4S, prescribed primarily to prevent postmenopausal osteoporosis.
Translations

raloxifene

n raloxifeno
References in periodicals archive ?
Raloxifene hydrochloride, a pale yellow solid which is slightly soluble in water [4,5].
Chugai ) Head Office: Chuo-ku, Tokyo; Chairman & CEO: Osamu Nagayama have agreed to terminate the agreement regarding co-marketing of EVISTAA tablet 60mg (generic name: raloxifene hydrochloride, hereafter EVISTAA ), a treatment for osteoporosis in postmenopausal women, as of December 31, 2012.
The four SERMs currently marketed in the United States are clomiphene citrate, tamoxifen citrate, toremifene citrate, and raloxifene hydrochloride.
Evista, the brand name for raloxifene hydrochloride, is the first of a new class of drugs approved for the prevention of osteoporosis.
Raloxifene hydrochloride, sold under the brand name Evista, was designed to prevent brittle bone disease in older women.
Based on this ruling, the Court enjoined Teva from commencing the commercial launch of generic raloxifene hydrochloride tablets prior to the expiration date of those patents.
The drug raloxifene hydrochloride, sold under the brand name Evista, is designed to prevent brittle bone disease in postmenopausal women.
Evista, under the generic name of raloxifene hydrochloride, will be available as a preventive for postmenopausal American women in 60 mg tablets.